$687 Billion is the total value of SENZAR ASSET MANAGEMENT, LLC's 36 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 83.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OFIX | Sell | ORTHOFIX INTL N V | $4,555,710,000 | +38109.4% | 134,984 | -62.5% | 0.66% | -67.6% |
| ACHN | Sell | ACHILLION PHARMACEUTICALS IN | $4,277,290,000 | +55012.6% | 619,000 | -29.3% | 0.62% | -53.3% |
| MDXG | Sell | MIMEDX GROUP INC | $4,017,884,000 | +31981.5% | 416,361 | -61.5% | 0.58% | -72.8% |
| ACRX | Exit | ACELRX PHARMACEUTICALS INC | $0 | – | -798,381 | -100.0% | -0.58% | – |
| AGNPRA | Exit | ALLERGAN PLCpfd conv ser a | $0 | – | -4,900 | -100.0% | -0.88% | – |
| XENT | Exit | INTERSECT ENT INC | $0 | – | -233,757 | -100.0% | -1.15% | – |
| PMC | Exit | PHARMERICA CORP | $0 | – | -229,214 | -100.0% | -1.31% | – |
| ESRX | Exit | EXPRESS SCRIPTS HLDG CO | $0 | – | -93,300 | -100.0% | -1.42% | – |
| SGNT | Exit | SAGENT PHARMACEUTICALS INC | $0 | – | -453,392 | -100.0% | -1.89% | – |
| DYAX | Exit | DYAX CORP | $0 | – | -440,433 | -100.0% | -2.00% | – |
| KND | Exit | KINDRED HEALTHCARE INC | $0 | – | -576,876 | -100.0% | -2.01% | – |
| ESPR | Exit | ESPERION THERAPEUTICS INC NE | $0 | – | -153,900 | -100.0% | -2.16% | – |
| JNJ | Exit | JOHNSON & JOHNSON | $0 | – | -171,400 | -100.0% | -2.87% | – |
| MDT | Exit | MEDTRONIC PLC | $0 | – | -228,400 | -100.0% | -2.91% | – |
| RCPT | Exit | RECEPTOS INC | $0 | – | -89,800 | -100.0% | -2.93% | – |
| BDX | Exit | BECTON DICKINSON & CO | $0 | – | -146,900 | -100.0% | -3.57% | – |
| PRGO | Exit | PERRIGO CO PLC | $0 | – | -198,100 | -100.0% | -6.29% | – |
| LH | Exit | LABORATORY CORP AMER HLDGS | $0 | – | -422,900 | -100.0% | -8.80% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CONCERT PHARMACEUTICALS INC | 16 | Q2 2018 | 4.5% |
| SANOFI | 14 | Q2 2018 | 17.6% |
| CORIUM INTL INC | 14 | Q3 2017 | 2.3% |
| FOAMIX PHARMACEUTICALS LTD | 14 | Q2 2018 | 2.1% |
| RETROPHIN INC | 13 | Q2 2017 | 3.0% |
| ALDER BIOPHARMACEUTICALS INC | 12 | Q2 2018 | 3.9% |
| RIGEL PHARMACEUTICALS INC | 12 | Q3 2016 | 1.8% |
| INSMED INC | 11 | Q3 2017 | 6.2% |
| TEVA PHARMACEUTICAL INDS LTD | 10 | Q1 2016 | 12.3% |
| ORTHOFIX INTL N V | 10 | Q1 2017 | 9.0% |
View SENZAR ASSET MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corium International, Inc.Sold out | February 14, 2018 | 0 | 0.0% |
| Aviragen Therapeutics, Inc. | February 13, 2017 | 1,774,876 | 4.6% |
| CONCERT PHARMACEUTICALS, INC. | February 13, 2017 | 400,588 | 1.8% |
| Foamix Pharmaceuticals Ltd. | February 13, 2017 | 550,997 | 1.5% |
| NEVRO CORPSold out | February 13, 2017 | 0 | 0.0% |
| TIVITY HEALTH, INC. | February 13, 2017 | 383,200 | 1.0% |
| HEALTHWAYS, INC | February 12, 2016 | 2,525,044 | 7.0% |
| Sientra, Inc. | February 12, 2016 | 580,851 | 3.2% |
| Biota Pharmaceuticals, Inc. | January 15, 2016 | 2,025,976 | 5.2% |
View SENZAR ASSET MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-10-31 |
| 13F-HR | 2018-08-13 |
| 13F-HR | 2018-05-14 |
| SC 13G/A | 2018-02-14 |
| 13F-HR | 2018-02-13 |
| 13F-HR | 2017-11-13 |
| 13F-HR | 2017-08-11 |
| 13F-HR | 2017-05-12 |
| 13F-HR | 2017-02-14 |
| SC 13G/A | 2017-02-13 |
View SENZAR ASSET MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.